Please assess the completion status of the following clinical trial:

Trial Title: Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical signs and symptoms of heart failure according to the ESC guidelines~* Echocardiographic evidence of a preserved systolic left ventricular function (echocardiographic left ventricular ejection fraction \> 50%)~* Polysomnographic evidence of at least moderate sleep-disordered breathing: apnea-hypopnea index (AHI) \> 15 / h with ≥ 50% central events and with with a central AHI of ≥ 10/h (AHI based on total sleeping time, TST)~* BNP or NT-pro BNP ≥ 300 pg / ml~* NYHA class II or III~* Patient tolerates the ventilation treatment (1h sample ventilation)~* Stable drug therapy in the last 4 weeks prior to randomization (no iv diuretic therapy or increasing the dose of diuretics to ≥ 100%)~* Minimum age of patients of 18 years~* patient willing to undergo study procedures~* signed informed consent~Exclusion Criteria:~* Oxygen saturation (sO2) \<92% of the days in peace without O2 therapy, measured baseline (start time) in the pulse oximetry or polysomnography in a cape. BGA (the measurement must be max. Lie back 1 week)~* Patients, who have a risk professional with symptomatic sleep apnea~* Known COPD with FEV1 \<70%~* patients with NYHA stadium IV~* Advanced congenital heart defects~* pericardial diseases~* Existing PAP or bi-level therapy (including adaptive servo-ventilation) in the last 3 months~* Acute cardiac event in the last 3 months~* BMI ≥ 35kg / m²~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adaptive servo ventilation (ASV) (Type: EXPERIMENTAL): This group will receive ventilation therapy (AutoSet CS, ASV device)

Based on this trial design, predict the completion outcome and termination type (if applicable).